Search

everythinglearnresearchcommunity

for

Search:↓

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

QLT0267 stops hair follicle cell growth and movement.

The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

Dacomitinib can cause nail and skin issues, but these can be managed without stopping the drug.

Nilotinib can cause keratosis pilaris, a skin condition.

Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Finasteride increases CD8+ T cells in BPH tissues.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.

Inclisiran is effective at lowering cholesterol.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.

Certain hydroxycinnamate derivatives may effectively inhibit enzymes linked to hair loss with low toxicity.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.